Cat. No. 4518
Chemical Name: N-(3-Ethoxyphenyl)-4-(1-pyrrolidiny
Biological ActivityTrace amine 1 (TA1) receptor antagonist/inverse agonist; exhibits a higher potency at the mouse TA1 receptor than the rat and human TA1 receptors (IC50 values are 27.5, 4539 and 7487 nM, respectively). Blocks the TA1 receptor-mediated activation of an inwardly rectifying K+ current, which increases the firing frequency of dopamine (DA) neurons in the ventral tegmental area. Increases DA potency at the D2 receptor. Also displays inverse agonism, reducing basal cAMP levels in vitro (IC50 = 19 nM).
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Bradaia et al (2009) The selective antagonist EPPTB reveals TAAR1-mediated regulatory mechanisms in dopaminergic neurons of the mesolimbic system. Proc.Natl.Acad.Sci.U.S.A. 106 20081. PMID: 19892733.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses EPPTB from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: EPPTB, supplier, Parkinson's, disease, trace, amine-associated, receptors, 1, TAAR1, antagonists, dopamine, neurons, neurones, TA1, Tocris Bioscience, Trace Amine 1 Receptor Antagonist products
Find multiple products by catalog number
New Products in this Area
Potent FFA1 (GPR40) agonistCATPB
FFA2 antagonist/inverse agonistOleanolic acid
Selective GPBA receptor (TGR5) partial agonistPPTN hydrochloride
High affinity and selective P2Y14 antagonistItraconazole
SMO antagonist; acts at different binding site to cyclopamine (Cat No. 1623)SAR 216471 hydrochloride
Potent P2Y12 antagonist; orally availableA 971432
Potent and selective S1P5 agonistGLPG 0974
Potent FFA2 antagonistOgerin
Selective positive allosteric modulator at GPR68BGC 20-1531 hydrochloride
High affinity and selective EP4 antagonistMontelukast sodium
CysLT1 and GPR17 antagonist
November 12 - 16, 2016
San Diego, CA, USA